In recent years, the development of immune checkpoint inhibitors (ICIs), such as anti-cytotoxic T lymphocyte-associated protein 4 and anti-PD-1/PD-L1, has led to significant breakthroughs in anti-tumor therapy.16 This evidence concerns the gene CTLA4 and neoplasm.